Locally injected Infliximab ameliorates murine DSS colitis: Differences in serum and intestinal levels of drug between healthy and colitic mice

Digestive and Liver Disease

Volumn 45, Issue 12, 2013, Pages 1017-1021

  Lopetuso, Loris Riccardo ^a   Petito, Valentina ^a   Cufino, Valerio ^a   Arena, Vincenzo ^a   Stigliano, Egidio ^a   Gerardi, Viviana ^a   Gaetani, Eleonora ^a   Poscia, Andrea ^a   Amato, Arianna ^a   Cammarota, Giovanni ^a   Papa, Alfredo ^a   Sgambato, Alessandro ^a   Gasbarrini, Antonio ^a   Scaldaferri, Franco ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Faeces; Inflammatory bowel disease; Infliximab; Intestinal mucosa; Murine DSS colitis; Pharmacokinetic; Serum levels

Indexed keywords

DEXTRAN SULFATE; ENEMA; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C57BL 6 MOUSE; COLITIS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FECES LEVEL; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG TISSUE LEVEL; ELISA KIT; HISTOLOGY; INTESTINE MUCOSA; MOUSE; MURINE MODEL; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; TREATMENT RESPONSE;

FAECES; INFLAMMATORY BOWEL DISEASE; INFLIXIMAB; INTESTINAL MUCOSA; MURINE DSS COLITIS; PHARMACOKINETIC; SERUM LEVELS;

ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, RECTAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; COLITIS; DEXTRAN SULFATE; ENEMA; FECES; INTESTINAL MUCOSA; MICE; MICE, INBRED C57BL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84887135112     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2013.06.007     Document Type: Article

References (16)

1. Strober W., Fuss I., Mannon P. The fundamental basis of inflammatory bowel disease. Journal of Clinical Investigation 2007, 117:514-521.
2. MacDonald T.T., Monteleone G., Pender S.L. Recent developments in the immunology of inflammatory bowel disease. Scandinavian Journal of Immunology 2000, 51:2-9.
3. Scallon B.J., Moore M.A., Trinh H., et al. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 1995, 7:251-259.
4. Lugering A., Schmidt M., Lugering N., et al. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 2001, 121:1145-1157.
5. ten Hove T., van Montfrans C., Peppelenbosch M.P., et al. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 2002, 50:206-211.
6. Marini M., Bamias G., Rivera-Nieves J., et al. TNF-alpha neutralization ameliorates the severity of murine Crohn's-like ileitis by abrogation of intestinal epithelial cell apoptosis. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:8366-8371.
7. Di Sabatino A., Pender S.L., Jackson C.L., et al. Functional modulation of Crohn's disease myofibroblasts by anti-tumor necrosis factor antibodies. Gastroenterology 2007, 133:137-149.
8. Di Sabatino A., Ciccocioppo R., Armellini E., et al. Serum bFGF and VEGF correlate respectively with bowel wall thickness and intramural blood flow in Crohn's disease. Inflammatory Bowel Disease 2004, 10:573-577.
9. Fries W., Muja C., Crisafulli C., et al. Infliximab and etanercept are equally effective in reducing enterocyte apoptosis in experimental colitis. International Journal of Medical Sciences 2008, 5(4):169-180.
10. Fries W., Muja C., Crisafulli C., et al. Dynamics of enterocyte tight junctions: effect of experimental colitis and two different anti-TNF strategies. American Journal of Physiology - Gastrointestinal and Liver Physiology 2008, 294:G938-G947.
11. Yamakawa I., Kojima H., Terashima T., et al. Inactivation of TNF-alpha ameliorates diabetic neuropathy in mice. American Journal of Physiology - Endocrinology and Metabolism 2011, 301:E844-E852.
12. Poggioli G., Laureti S., Pierangeli F., et al. Local injection of Infliximab for the treatment of perianal Crohn's disease. Diseases of the Colon & Rectum 2005, 48:768-774.
13. Shen C., de Hertogh G., Bullens D.M., et al. Remission-inducing effect of anti-TNF monoclonal antibody in TNBS colitis: mechanisms beyond neutralization?. Inflammatory Bowel Diseases 2007, 13:308-316.
14. Mattson M.P., Haberman F. Folate and homocysteine metabolism: therapeutic targets in cardiovascular and neurodegenerative disorders. Current Medicinal Chemistry 2003, 10:1923-1929.
15. Calkins B.M. A meta-analysis of the role of smoking in inflammatory bowel disease. Digestive Diseases and Sciences 1989, 34:1841-1854.
16. Bossen C., Ingold K., Tardivel A., et al. Interactions of tumor necrosis factor (TNF) and TNF receptor family members in the mouse and human. Journal of Biological Chemistry 2006, 281:13964-13971.